GOCO Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
GoHealth Inc (GOCO) is not a strong buy at the moment for a beginner investor with a long-term focus. While the stock has shown a recent price increase, the company's financial performance is significantly weak, and analysts have downgraded the stock with a cautious outlook for 2026. The absence of strong proprietary trading signals and lack of positive momentum in technical indicators further supports a hold recommendation.
The MACD histogram is negative and contracting, indicating weak momentum. RSI is neutral at 50.783, showing no clear signal. Moving averages are bearish (SMA_200 > SMA_20 > SMA_5), and the stock is trading between key support and resistance levels (Pivot: 1.177, R1: 1.328, S1: 1.026). Overall, the technical indicators suggest a lack of strong upward momentum.
The company is focusing on strategic investments in Special Needs Plans, automation, and artificial intelligence to improve operational efficiency. Additionally, GoHealth is working to protect $925 million in commissions receivable, which may enhance financial stability in the long term.
Analysts have downgraded the stock to Hold with a reduced price target, citing weak Medicare Advantage commission economics and a cautious outlook for 2026.
In Q4 2025, revenue dropped to $12.639 million (-96.75% YoY), net income fell to -$33.602 million (-236.76% YoY), and EPS declined to -2.09 (-186.36% YoY). Gross margin also dropped to 65.59 (-18.55% YoY). These figures indicate severe financial underperformance.
Freedom Broker downgraded GoHealth to Hold from Buy, with a reduced price target of $1.50 (down from $4.50). Analysts are cautious about the company's rebound potential in 2027 and see a weak 2026 outlook.
